NCT06778265 - An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Parkinson Disease, Idiopathic

Interventions

BIOLOGICAL

UX-DA001

"UX-DA001 (Human Midbrain Dopaminergic Progenitor Cells) is used for treating patients with iPD via implanting into bilateral putamina under stereotactic neurosurgery.~Two dose levels will be planned. Each patient only receives one corresponding dose of UX-DA001."

Trial Locations (1)

200025

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

collaborator

Ruijin Hospital

OTHER

lead

Shanghai UniXell Biotechnology Co., Ltd

INDUSTRY